TGA warns fake Ozempic pens imported to Australia 4 November 2024 Counterfeit Ozempic-labelled pens are being sold in Australia. The Therapeutic Goods Administration (TGA) and the Australian Border Force (ABF) have detected the fake Ozempic-labelled pens. The TGA is warning people to look for spelling errors, instruction leaflets not in English, unsealed packaging, or changes in medicine size, shape, or appearance. These are indicators that the medicine has not been produced by the original manufacturer or is being illegally sold in the wrong market. The two products which have prompted the alert both appear to be relabelled insulin pens. The end ap is blue (not grey), the dosage barrel is in a different place, the sticker is not adhering properly to the pen, and the packaging is poor quality. There has already been a life-threatening incident in Australia with a person using a fake pen labelled as Ozempic which contained insulin. This pen was bought overseas. Unintended use of insulin can cause dangerously low life-threatening blood glucose levels. The batch numbers labelled on the pens - NPSG234 detected by ABF and JS7A925 from the adverse event – have been confirmed as not genuine batch numbers by Novo Nordisk, the manufacturer of Ozempic. The ABF said the products were purchased online from an overseas website and imported under the personal importation scheme.
Media releases 14 August 2026 Beyond blood glucose: New national partnership to measure how Australians with diabetes are really doing For the first time, the Australian Unity Wellbeing Index will be used to build the most complete picture yet of how diabetes affects Australian’s lives beyond clinical outcomes and health system costs, thanks to a partnership between Diabetes Australia, Deakin University, and the Australian Unity Support Foundation. Continue Reading
Media releases 13 August 2026 PMOS in spotlight for diabetes prevention A new partnership between Diabetes Australia and the Medibank Better Health Research Hub will support Monash University to develop a primary care model to better detect and prevent type 2 diabetes in women living with polyendocrine metabolic ovarian syndrome (PMOS). Continue Reading
News 7 August 2026 Brett Fenton appointed Adjunct Clinical Fellow at UTS Diabetes Australia warmly welcomes Chief Health Officer Brett Fenton's appointment as an Adjunct Clinical Fellow at the University of Technology Sydney (UTS). Continue Reading